Enhanced CAR-T Cell Therapy Shows Promise Against Treatment-Resistant Blood Cancers
Modified immune cells engineered to overcome cancer's defenses completed safety testing in lymphoma patients.
32 articles in this topic
Modified immune cells engineered to overcome cancer's defenses completed safety testing in lymphoma patients.
Engineered immune cells target liver cancer protein in phase I safety study, though trial ended early with 10 patients.
Phase 1 trial tests innovative immunotherapy for multiple myeloma and lymphoma patients who didn't respond to standard treatments.
Stanford researchers used smartwatches and blood tests to monitor dangerous side effects during cutting-edge CAR-T cancer treatment.
Small trial tests novel three-drug approach combining immune checkpoint inhibitor, vaccine, and inflammation blocker for metastatic cancers.
Study examines bone density loss in melanoma patients receiving immune-boosting cancer drugs like nivolumab and pembrolizumab.
Autologous NK cell therapy combined with immunotherapy tested in 27 patients with treatment-resistant cancers.
HIIT training studied in 52 men with prostate cancer on active surveillance to evaluate exercise benefits during watchful waiting.
Small study explores cerebrospinal fluid exosomes to better diagnose breast cancer spread to brain and spinal cord.
New diagnostic chip analyzes blood exosomes to detect early lung spread of bone cancer, potentially improving treatment outcomes.
Small trial tests innovative immune cell therapy for patients with relapsed non-Hodgkin's lymphoma who failed standard treatments.
Genetically modified immune cells target blood cancer that stopped responding to standard treatments in 28-patient trial.